ambrisentan / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 46 Diseases   10 Trials   10 Trials   738 News 


«12345678910»
  • ||||||||||  Thelin (oral sitaxsentan) / Pfizer, Tracleer (bosentan) / J&J, Roche
    Biomarker, Enrollment change, Trial withdrawal:  Pharmacogenomics in Pulmonary Arterial Hypertension (clinicaltrials.gov) -  Dec 9, 2021   
    P=N/A,  N=0, Withdrawn, 
    N=1300 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  sildenafil / Generic mfg., enoxaparin sodium / Generic mfg.
    Pulmonary arterial hypertension (PAH) during pregnancy – an anaesthetic challenge ([VIRTUAL]) -  Oct 21, 2021 - Abstract #Euroanaesthesia2021Euroanaesthesia_487;    
    The disease was controlled with ambrisentan, sildenafil, immunosuppressive drugs and warfarin...Regional technique was not performed because of recent administration of therapeutic dose of enoxaparin...Remifentanil infusion was used to limit the cardiovascular response during intubation and anaesthetic emergence...General anaesthesia with focus on haemodynamic stability was offered and safely performed.Learning points:This case highlights the importance of monitoring highrisk pregnancies in a central hospital to minimize morbidity and mortality associated with this disease. Epoprostenol proved to be a useful therapy in the peripartum period, in accordance to medical literature2 .
  • ||||||||||  tilarginine (L-NMMA) / Arginox Pharma, Houston Methodist Research Institute, NN1213 / Novo Nordisk
    Trial completion:  Mechanisms of Cerebrovascular Control (clinicaltrials.gov) -  Oct 18, 2021   
    P1,  N=59, Completed, 
    Epoprostenol proved to be a useful therapy in the peripartum period, in accordance to medical literature2 . Active, not recruiting --> Completed
  • ||||||||||  lorazepam / Generic mfg.
    [VIRTUAL] PROSTACYCLIN'S, PULMONARY HYPERTENSION, AND END OF LIFE CARE () -  Oct 13, 2021 - Abstract #CHEST2021CHEST_2287;    
    There is minimal evidence regarding the use of PC therapy during palliation for patients with advanced PAH. Following the implementation of a Prostacyclin End of Life Titration Protocol, we hope to provide optimal comfort and pain control for end of life PAH patients.
  • ||||||||||  cetirizine oral / Generic mfg., spironolactone / Generic mfg., epoprostenol intravenous / Generic mfg.
    [VIRTUAL] SEVERE THROMBOCYTOPENIA DUE TO IV EPOPROSTENOL: DON'T MUCK WITH THE PLATELETS () -  Oct 13, 2021 - Abstract #CHEST2021CHEST_2256;    
    It appears to have a dose-dependent relationship and may improve with changing to an alternative prostacyclin. It is critical to recognize this phenomenon as profound thrombocytopenia can not only be dangerous, but also preclude lung transplant candidacy, should it become necessary
  • ||||||||||  ambrisentan / Generic mfg.
    Trial completion date, Trial primary completion date:  A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19 (clinicaltrials.gov) -  Aug 18, 2021   
    P2,  N=150, Recruiting, 
    So, combination therapy of pulmonary vasodilators should not be applied in all patients with CTD-PH since underlying PVOD could deteriorate the patient's condition. Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Jul 2021 --> Jul 2022
  • ||||||||||  ambrisentan / Generic mfg.
    Trial completion date, Trial primary completion date:  Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529 (clinicaltrials.gov) -  Aug 18, 2021   
    P2,  N=66, Active, not recruiting, 
    Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Jul 2021 --> Jul 2022 Trial completion date: Jun 2024 --> Jan 2022 | Trial primary completion date: Jun 2022 --> Jan 2022
  • ||||||||||  tilarginine (L-NMMA) / Arginox Pharma, Houston Methodist Research Institute, NN1213 / Novo Nordisk
    Enrollment closed:  Mechanisms of Cerebrovascular Control (clinicaltrials.gov) -  Aug 4, 2021   
    P1,  N=59, Active, not recruiting, 
    Trial completion date: Jun 2024 --> Jan 2022 | Trial primary completion date: Jun 2022 --> Jan 2022 Recruiting --> Active, not recruiting
  • ||||||||||  [VIRTUAL] EFFECTS OF FACE-TO-FACE EDUCATIONAL NURSING SUPPORT ON PATIENT COMPLIANCE WITH ORAL PAH THERAPIES () -  Apr 11, 2021 - Abstract #AMCP2021AMCP_128;    
    Patients receiving oral PAH therapies in an educational nursing program demonstrated a positive effect on overall medication compliance as demonstrated by a statistically significant improvement in MPR and therapy persistence. While our study compared two different PAH therapy classes, a multidisciplinary patient support approach contributed to improved patient outcomes.
  • ||||||||||  Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
    Clinical, Review, Combination therapy:  Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia (Pubmed Central) -  Mar 23, 2021   
    Some beneficial pharmacological effects due to the synergy between ambrisentan plus riociguat, and inhaled iloprost plus sildenafil appear to be interesting and require further clinical confirmation. Other initial combinations of PAH-specific agents require large-scale clinical trials as well.
  • ||||||||||  Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, EDP1815 / Evelo Biosci
    Trial completion date, Trial primary completion date:  TACTIC-E: mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (clinicaltrials.gov) -  Mar 19, 2021   
    P2/3,  N=1407, Recruiting, 
    Other initial combinations of PAH-specific agents require large-scale clinical trials as well. Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Feb 2021 --> Feb 2022
  • ||||||||||  ambrisentan / Generic mfg., tadalafil / Generic mfg.
    [VIRTUAL] Pulmonary Veno-Occlusive Disease Due to Biallelic EIF2AK4 Gene Mutation () -  Mar 14, 2021 - Abstract #ATS2021ATS_4634;    
    Given the poor prognosis of this diagnosis, he was referred for urgent transplant assessment. This is an interesting case of PVOD which highlights the specific diagnostic and prognostic role of genetic testing in these complex and rare cases.
  • ||||||||||  amphetamine / Generic mfg.
    [VIRTUAL] Pulmonary Arterial Hypertension and Arrhythmogenic Right Ventricular Cardiomyopathy () -  Mar 14, 2021 - Abstract #ATS2021ATS_3475;    
    Case Presentation:A 40-year-old woman with a prior history of Amphetamine and Marijuana use presented with worsening exertional dyspnea, weight gain and pedal edema...She was diagnosed with WHO group 1 Pulmonary Arterial Hypertension (PAH), NYHA class III and started on Ambrisentan, and Tadalafil...The presence of PAH with ARVC makes it difficult for patients to become candidates for a heart transplant due to challenges in the appropriate reduction of mPAP for better post-transplant outcomes. Therefore, these patients should be triaged early to become candidates for a Heart and Lung Transplant as opposed to isolated Heart or Double Lung Transplants to treat both the PAH and ARVC.
  • ||||||||||  ambrisentan / Generic mfg., tadalafil / Generic mfg.
    [VIRTUAL] Resolution of Portopulmonary Hypertension After Liver Transplantation () -  Mar 14, 2021 - Abstract #ATS2021ATS_2319;    
    Possible mechanism for recovery of pulmonary hypertension post liver transplantation include 1) decreased pulmonary vascular wall shear stress, 2) decreased portosystemic shunting with bacterial endotoxin, 3) decreased splanchnic vasoactive substances, 4) decreased endothelin-1, and 5) increased nitric oxide/prostaglandin I2 production. Additional research is needed to determine which patients are most likely to benefit from improvement in their portopulmonary hypertension post transplant and to guide monitoring and tapering of pulmonary arterial hypertension directed therapies post transplant.
  • ||||||||||  ambrisentan / Generic mfg., midodrine hydrochloride / Generic mfg., tadalafil / Generic mfg.
    [VIRTUAL] Precapillary Pulmonary Arterial Hypertension in ESRD: A Forgotten Group () -  Mar 14, 2021 - Abstract #ATS2021ATS_337;    
    The majority of patients were middle aged females (Table 1). The etiology for renal disease was identified in 17/18 patients with scleroderma being the most common etiology (Table 1).
  • ||||||||||  ambrisentan / Generic mfg.
    Trial termination, Trial primary completion date:  A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis (clinicaltrials.gov) -  Feb 26, 2021   
    P2,  N=19, Terminated, 
    The etiology for renal disease was identified in 17/18 patients with scleroderma being the most common etiology (Table 1). Recruiting --> Terminated | Trial primary completion date: Sep 2020 --> Dec 2020; Lack of recruitment, result of COVID-19 pandemic
  • ||||||||||  Opsumit (macitentan) / Nippon Shinyaku, J&J
    Journal:  Transfer and Vascular Effect of Endothelin Receptor Antagonists in the Human Placenta. (Pubmed Central) -  Feb 25, 2021   
    Given its limited transfer, macitentan could be considered as potential preeclampsia therapy. Extending knowledge on placental transfer to placentas of preeclamptic pregnancies is required to determine whether ERAs might be applied safely in preeclampsia.